Introduction The World Health Organization declared the coronavirus disease 2019 (COVID-
19) pandemic on March 11, 2020. Two vaccine types were developed using two different …

Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic
autoimmune complications. Adverse events (AEs) of this nature had been previously …

Abstract Background The Ad26. COV2. S vaccine was highly effective against severe–
critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase …

The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …

Cerebral venous thrombosis accounts for 0.5% to 3% of all strokes. The most vulnerable
populations include young individuals, women of reproductive age, and patients with a …

The COVID-19 pandemic triggered a sense of vulnerability and urgency that led to
concerted actions by governments, funders, regulators and industry to overcome traditional …

Within the first months of the COVID-19 vaccination campaign, previously healthy recipients
who developed severe thrombosis (often cerebral and/or splanchnic vasculature) and …

Background Different forms of vaccines have been developed to prevent the SARS‐CoV‐2
virus and subsequent COVID‐19 disease. Several are in widespread use globally …

Cerebral venous thrombosis (CVT) is a rare form of cerebrovascular disease that impairs
people's wellbeing and quality of life. Inflammation is considered to play an important role in …

Introduction: COVID-19 vaccines became available after being carefully monitored in clinical
trials with safety and efficacy on the human body. However, a few recipients developed …